Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07284667 · ClinicalTrials.gov registry record · Phase 2
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
A Phase 2 study of Major Depressive Disorder (MDD) and Depressive Disorder, Treatment-Resistant, sponsored by ACADIA Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 153
- Enrollment target
- 12
- Study locations
NCT07284667: Recruiting Phase 2 study of Major Depressive Disorder (MDD) and Depressive Disorder, Treatment-Resistant, sponsored by ACADIA Pharmaceuticals.
NCT07284667 is a Phase 2 study of Major Depressive Disorder (MDD) and Depressive Disorder, Treatment-Resistant that is actively recruiting participants, run by ACADIA Pharmaceuticals. The registered enrollment target is 153 participants, roughly in line with the 152-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target. The trial reports 12 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07284667, a Phase 2 study of Major Depressive Disorder (MDD) and Depressive Disorder, Treatment-Resistant, is actively recruiting participants, sponsored by ACADIA Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 153 participants
- Enrollment target
- 12
- Study locations
Study Summary
The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work better than a placebo (a look-alike capsule with no medicine) to reduce symptoms of depression? * What adverse events do participants have when taking ACP-211?
Primary Outcome
The MADRS is a clinician-rated scale that assesses the severity of depressive symptoms. It consists of 10 items, each scored from 0 (no symptoms) to 6 (severe symptoms), resulting in a total score range of 0 to 60. Higher scores indicate greater depression severity.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ACP-211
Study Locations (12)
Florida
- Sandhill Research, LLC/DBA Accel Research Sites - Largo
- Clinical Neuroscience Solutions, Inc. - Orlando
- IPTB Clinical Research - Tampa
Texas
- Dynamed Clinical Research LP d/b/a DM Clinical Research - Houston
- Olympus Clinical Research, LLC - Katy
California
- Inland Psychiatric Medical Group - Chino
Colorado
- Mountain View Clinical Research - Denver
Massachusetts
- Vitalix Clinical, Inc. - Worcester
Nevada
- Redbird Research LLC - Las Vegas
New Jersey
- CenExel Hassman Research Institute, LLC - Marlton
New York
- Integrative Clinical Trials LLC - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 153 participants |
| Start Date | 2025-11-14 |
| Est. Completion | 2027-09 |
| Phase | Phase 2 |
What NCT07284667 shows while recruiting
NCT07284667 is an interventional study that assigns participants to a tested intervention. The registered 153 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 152-participant average among 22 other Major Depressive Disorder (MDD) trials with a reported enrollment target.
The record links to 2 conditions, with Major Depressive Disorder (MDD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07284667 lists 12 locations in 9 states (Florida, Texas, California).
Frequently Asked Questions
What is clinical trial NCT07284667 about?
NCT07284667 is a clinical study titled "ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response". The goal of this clinical trial is to learn if ACP-211 can help treat adults with major depressive disorder (MDD) who have not improved with antidepressant therapy (ADT), including those with treatment resistant depression (TRD). The main questions the study aims to answer are: * Does ACP-211 work...
What is the current status of trial NCT07284667?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 153 participants. The study started on 2025-11-14. Estimated completion is 2027-09.
What conditions does trial NCT07284667 study?
This clinical trial studies the following conditions: Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant.
What interventions are being tested in trial NCT07284667?
The interventions under investigation include: Placebo (DRUG), ACP-211 (DRUG).
Who is sponsoring clinical trial NCT07284667?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07284667 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Massachusetts, Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder (MDD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07284667's enrollment target sits among peer trials
153 10th of 22 higher than 13 of 22 other Major Depressive Disorder (MDD) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder (MDD) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression
RECRUITING · Phase 2
-
Orexin Antagonism for Suicide Risk: A Proof-of-Concept Clinical Trial
RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy and Safety of SPT-300 (GlyphAllo) in Participants With Major Depressive Disorder, With or Without Anxious Distress (BUOY-1 Study)
RECRUITING · Phase 2
-
Study to Evaluate Efficacy and Safety of Ropanicant in MDD Patients
ACTIVE NOT RECRUITING · Phase 2
-
A Study in Patients With Major Depressive Disorder
ACTIVE NOT RECRUITING · Phase 2
-
Improving Depression Outcome by Enhancing Memory for Cognitive Therapy
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05283265 · 153 participants · NA
Neurophysiological Mechanisms of Language Comprehension
- NCT05554393 · 153 participants · Phase 2
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- NCT05584501 · 153 participants · NA
ETE Interventions in the Dental Setting
- NCT05714839 · 153 participants · Phase 1
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI